Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BNIP3P8 is annotated as a pseudogene related to BNIP3, part of the BCL2-interacting protein family, but there is no evidence it encodes a functional protein or acts as a drug target. Its name is derived from similarity to BNIP3, a well-characterized pro-apoptotic protein involved in cell death and autophagy, but pseudogenes like BNIP3P8 do not typically produce functional proteins or have recognized molecular functions or disease associations. The correct target for apoptosis-related functions would be "BCL2/adenovirus E1B 19 kDa protein-interacting protein 3" (BNIP3) rather than BNIP3P8. BNIP3P8 is a pseudogene and not a receptor, enzyme, transporter, or otherwise validated therapeutic target. Most molecular and functional information pertains to BNIP3, a true gene/protein, not BNIP3P8. Therefore, there is something incorrect with selecting BNIP3P8 as a target for drug development or biological studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 8 (BNIP3P8).